Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases? (Q34286137)

1 August 2017

title

Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases? (English)

1 reference

1 August 2017

0 references

John Heineman

1

1 reference

1 August 2017

Sara Bubenik

series ordinal

2

1 reference

1 August 2017

Stephen McClave

series ordinal

3

1 reference

1 August 2017

Robert Martindale

series ordinal

4

1 reference

1 August 2017

language of work or name

1 reference

1 August 2012

1 reference

Current gastroenterology reports

1 August 2017

published in

1 reference

1 August 2017

volume

14

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

343-348

1 reference

Lactic Acid Bacteria and Human Health

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Helicobacter pyloriInfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Helicobacter pylori treatment in the era of increasing antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Comparative effectiveness of Clostridium difficile treatments: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Probiotics and prevention of neonatal necrotizing enterocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Postoperative pulmonary complications: pneumonia and acute respiratory failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Perspectives in surgical infections: what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

The dominant sequence types of vancomycin-resistant Enterococcus faecium among transplantation ward patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

The role of the gut microbiota in energy metabolism and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0274-4

Nonalcoholic fatty liver disease

21 January 2018

1 reference

12 December 2020

Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis

1 reference

12 December 2020

Probiotics for recurrent Clostridium difficile disease

1 reference

12 December 2020

An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children

1 reference

12 December 2020

Probiotics for prevention of necrotizing enterocolitis in preterm infants

1 reference

12 December 2020

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii

1 reference

12 December 2020

Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro

1 reference

12 December 2020

Using the good to beat out the bad: probiotics for eliminating vancomycin-resistant enterococci colonization

1 reference

12 December 2020

Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri

1 reference

12 December 2020

Probiotics for treatment of Clostridium difficile-associated colitis in adults

1 reference

12 December 2020

Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial

1 reference

12 December 2020

10.1007/S11894-012-0274-4

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1036811580

0 references

1 reference